PetMed Express (PETS) director awarded 34,866 restricted shares

PetMed Express (PETS) reported a director’s acquisition of 34,866 shares of restricted common stock on 10/30/2025 at $0, as disclosed in a Form 4.

Rhea-AI Filing Summary

PetMed Express (PETS) reported a director’s acquisition of 34,866 shares of restricted common stock on 10/30/2025 at $0, as disclosed in a Form 4. Following the award, the director beneficially owns 34,866 shares, held directly. The grant was made under the company’s 2024 Omnibus Incentive Plan and is scheduled to vest in two tranches: 1,020 shares on 10/19/2026 and 33,846 shares on 10/30/2026, each vesting subject to continued service on the Board of Directors.

Insider Trade Summary

Grant/Award: 34,866 shares

Grant/Award 1 txn

Insider LaCamp James

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,866	$0.00	$0.00

Holdings After Transaction: Common Stock — 34,866 shares (Direct)

Footnotes (1)

1. F1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan , of which 1,020 shares will vest on October 19, 2026 and 33,846 shares will vest on October 30, 2026, subject to continued service on the Board of Directors.

FAQ

What did PetMed Express (PETS) disclose in this Form 4?

A director acquired 34,866 restricted shares on 10/30/2025 at $0 under the 2024 Omnibus Incentive Plan.

How many shares does the reporting person own after the transaction?

The reporting person beneficially owns 34,866 shares directly following the award.

What is the vesting schedule for the restricted shares?

Vesting occurs in two tranches: 1,020 shares on 10/19/2026 and 33,846 shares on 10/30/2026, subject to continued Board service.

Was there a purchase price for the restricted stock award?

The reported price was $0, reflecting a grant of restricted shares rather than an open-market purchase.

Under which plan were the shares granted?

The shares were granted under the PetMed Express, Inc. 2024 Omnibus Incentive Plan.

What role does the reporting person hold at PetMed Express (PETS)?

The reporting person is a Director of PetMed Express.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaCamp James

(Last) (First) (Middle)

C/O PETMED EXPRESS, INC.

420 S CONGRESS AVENUE

(Street)

DELRAY BEACH FL 33445

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PETMED EXPRESS INC [ PETS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		A		34,866(1)	A	$0	34,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan , of which 1,020 shares will vest on October 19, 2026 and 33,846 shares will vest on October 30, 2026, subject to continued service on the Board of Directors.

Remarks:

	/s/ James LaCamp	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.